<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">1524</journal-id><journal-id journal-id-type="pmc-domain">frontpharmacol</journal-id><journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id><journal-title-group><journal-title>Frontiers in Pharmacology</journal-title></journal-title-group><issn pub-type="epub">1663-9812</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11605395</article-id><article-id pub-id-type="pmcid-ver">PMC11605395.1</article-id><article-id pub-id-type="pmcaid">11605395</article-id><article-id pub-id-type="pmcaiid">11605395</article-id><article-id pub-id-type="pmid">39619609</article-id><article-id pub-id-type="doi">10.3389/fphar.2024.1437400</article-id><article-id pub-id-type="publisher-id">1437400</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Population pharmacokinetics of rilpivirine following oral administration and long-acting intramuscular injection in real-world people with HIV</article-title><alt-title alt-title-type="left-running-head">Thoueille et al.</alt-title><alt-title alt-title-type="right-running-head"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.3389/fphar.2024.1437400" ext-link-type="uri">10.3389/fphar.2024.1437400</ext-link></alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Thoueille</surname><given-names initials="P">Paul</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2749138/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Saldanha</surname><given-names initials="SA">Susana Alves</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schaller</surname><given-names initials="F">Fabian</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Choong</surname><given-names initials="E">Eva</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/600387/overview"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Veuve</surname><given-names initials="F">Fran&#231;ois</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Munting</surname><given-names initials="A">Aline</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cavassini</surname><given-names initials="M">Matthias</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Braun</surname><given-names initials="D">Dominique</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>G&#252;nthard</surname><given-names initials="HF">Huldrych F.</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/58862/overview"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Duran Ramirez</surname><given-names initials="JJ">Jessy J.</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Surial</surname><given-names initials="B">Bernard</given-names></name><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Furrer</surname><given-names initials="H">Hansjakob</given-names></name><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rauch</surname><given-names initials="A">Andri</given-names></name><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ustero</surname><given-names initials="P">Pilar</given-names></name><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Calmy</surname><given-names initials="A">Alexandra</given-names></name><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref><xref rid="aff8" ref-type="aff">
<sup>8</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>St&#246;ckle</surname><given-names initials="M">Marcel</given-names></name><xref rid="aff9" ref-type="aff">
<sup>9</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Di Benedetto</surname><given-names initials="C">Caroline</given-names></name><xref rid="aff10" ref-type="aff">
<sup>10</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bernasconi</surname><given-names initials="E">Enos</given-names></name><xref rid="aff11" ref-type="aff">
<sup>11</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schmid</surname><given-names initials="P">Patrick</given-names></name><xref rid="aff12" ref-type="aff">
<sup>12</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Marzolini</surname><given-names initials="C">Catia</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff9" ref-type="aff">
<sup>9</sup>
</xref><xref rid="aff13" ref-type="aff">
<sup>13</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Girardin</surname><given-names initials="FR">Fran&#231;ois R.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1654585/overview"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Buclin</surname><given-names initials="T">Thierry</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/840913/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Decosterd</surname><given-names initials="LA">Laurent A.</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1606751/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Guidi</surname><given-names initials="M">Monia</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff14" ref-type="aff">
<sup>14</sup>
</xref><xref rid="aff15" ref-type="aff">
<sup>15</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1325576/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><on-behalf-of>the Swiss HIV Cohort Study</on-behalf-of></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Service of Clinical Pharmacology</institution>, <institution>Department of Medicine</institution>, <institution>Lausanne University Hospital and University of Lausanne</institution>, <addr-line>Lausanne</addr-line>, <country>Switzerland</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Laboratory of Clinical Pharmacology</institution>, <institution>Department of Laboratory Medicine and Pathology</institution>, <institution>Lausanne University Hospital and University of Lausanne</institution>, <addr-line>Lausanne</addr-line>, <country>Switzerland</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Service of Infectious Diseases</institution>, <institution>Department of Medicine</institution>, <institution>Lausanne University Hospital and University of Lausanne</institution>, <addr-line>Lausanne</addr-line>, <country>Switzerland</country>
</aff><aff id="aff4">
<sup>4</sup>
<institution>Department of Infectious Diseases and Hospital Epidemiology</institution>, <institution>University Hospital Zurich</institution>, <addr-line>Zurich</addr-line>, <country>Switzerland</country>
</aff><aff id="aff5">
<sup>5</sup>
<institution>Institute of Medical Virology</institution>, <institution>University of Zurich</institution>, <addr-line>Zurich</addr-line>, <country>Switzerland</country>
</aff><aff id="aff6">
<sup>6</sup>
<institution>Department of Infectious Diseases</institution>, <institution>Inselspital, Bern University Hospital</institution>, <institution>University of Bern</institution>, <addr-line>Bern</addr-line>, <country>Switzerland</country>
</aff><aff id="aff7">
<sup>7</sup>
<institution>Division of Infectious Diseases</institution>, <institution>Geneva University Hospitals</institution>, <institution>Faculty of Medicine</institution>, <addr-line>Geneva</addr-line>, <country>Switzerland</country>
</aff><aff id="aff8">
<sup>8</sup>
<institution>Department of Medicine</institution>, <institution>Faculty of Medicine</institution>, <institution>University of Geneva</institution>, <addr-line>Geneva</addr-line>, <country>Switzerland</country>
</aff><aff id="aff9">
<sup>9</sup>
<institution>Division of Infectious Diseases and Hospital Epidemiology</institution>, <institution>University Hospital Basel</institution>, <institution>University of Basel</institution>, <addr-line>Basel</addr-line>, <country>Switzerland</country>
</aff><aff id="aff10">
<sup>10</sup>
<institution>Division of Infectious Diseases</institution>, <institution>Ente Ospedaliero Cantonale</institution>, <addr-line>Lugano</addr-line>, <country>Switzerland</country>
</aff><aff id="aff11">
<sup>11</sup>
<institution>Division of Infectious diseases</institution>, <institution>Ente Ospedaliero Cantonale</institution>, <institution>University of Geneva, and University of Southern Switzerland</institution>, <addr-line>Lugano</addr-line>, <country>Switzerland</country>
</aff><aff id="aff12">
<sup>12</sup>
<institution>Division of Infectious Diseases and Hospital Epidemiology</institution>, <institution>Cantonal Hospital St Gallen</institution>, <addr-line>St Gallen</addr-line>, <country>Switzerland</country>
</aff><aff id="aff13">
<sup>13</sup>
<institution>Department of Molecular and Clinical Pharmacology</institution>, <institution>Institute of Translational Medicine</institution>, <institution>University of Liverpool</institution>, <addr-line>Liverpool</addr-line>, <country>United Kingdom</country>
</aff><aff id="aff14">
<sup>14</sup>
<institution>Centre for Research and Innovation in Clinical Pharmaceutical Sciences</institution>, <institution>Lausanne University Hospital and University of Lausanne</institution>, <addr-line>Lausanne</addr-line>, <country>Switzerland</country>
</aff><aff id="aff15">
<sup>15</sup>
<institution>Institute of Pharmaceutical Sciences of Western Switzerland</institution>, <institution>University of Geneva</institution>, <institution>University of Lausanne</institution>, <addr-line>Geneva</addr-line>, <country>Switzerland</country>
</aff><author-notes><fn fn-type="edited-by"><p>
<bold>Edited by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/490557/overview" ext-link-type="uri">Gerardo Garcia-Lerma</ext-link>, Centers for Disease Control and Prevention (CDC), United States</p></fn><fn fn-type="edited-by"><p>
<bold>Reviewed by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1368543/overview" ext-link-type="uri">Dario Cattaneo</ext-link>, Luigi Sacco Hospital, Italy</p><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2046930/overview" ext-link-type="uri">Kristina Brooks</ext-link>, University of Colorado Anschutz Medical Campus, United States</p></fn><corresp id="c001">*Correspondence: Monia Guidi, <email>monia.guidi@chuv.ch</email></corresp></author-notes><pub-date pub-type="epub"><day>15</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>15</volume><issue-id pub-id-type="pmc-issue-id">454176</issue-id><elocation-id>1437400</elocation-id><history><date date-type="received"><day>23</day><month>5</month><year>2024</year></date><date date-type="accepted"><day>14</day><month>10</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>15</day><month>11</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>29</day><month>11</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-12-02 09:25:15.450"><day>02</day><month>12</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2024 Thoueille, Saldanha, Schaller, Choong, Veuve, Munting, Cavassini, Braun, G&#252;nthard, Duran Ramirez, Surial, Furrer, Rauch, Ustero, Calmy, St&#246;ckle, Di Benedetto, Bernasconi, Schmid, Marzolini, Girardin, Buclin, Decosterd and Guidi.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Thoueille, Saldanha, Schaller, Choong, Veuve, Munting, Cavassini, Braun, G&#252;nthard, Duran Ramirez, Surial, Furrer, Rauch, Ustero, Calmy, St&#246;ckle, Di Benedetto, Bernasconi, Schmid, Marzolini, Girardin, Buclin, Decosterd and Guidi</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fphar-15-1437400.pdf"/><abstract><sec><title>Background</title><p>The pharmacokinetics of long-acting rilpivirine has mostly been studied in clinical trials, which do not fully address the uncertainties that arise in routine clinical situations.</p></sec><sec><title>Aims and methods</title><p>Our population analysis aims to establish percentile curves for rilpivirine concentrations in people with HIV (PWH) followed-up in a routine clinical setting, while identifying patient-related factors that may influence rilpivirine exposure. A total of 238 PWH enrolled in our nationwide multicenter observational study contributed to 1038 concentrations (186 and 852 concentrations after oral and intramuscular injection, respectively).</p></sec><sec><title>Results</title><p>Rilpivirine pharmacokinetics were best described by a two-compartment model with an oral to intramuscular relative bioavailability factor. A simple zero-order absorption process was retained for oral administration while a parallel first-order absorption was used for intramuscular administration, with 27.6% of the dose released via a fast absorption pathway and the remaining fraction via a slow absorption pathway. Our model estimated that long-acting rilpivirine reaches steady-state after 2.5&#160;years and has an elimination half-life of 18&#160;weeks, consistent with published estimates. In females, a 45.6% reduction in the proportion of the dose absorbed via the rapid absorption pathway was observed. However, this resulted in no more than 15% difference in trough concentrations (C<sub>trough</sub>) compared to males, which was not considered to be clinically relevant.</p></sec><sec><title>Conclusion</title><p>Overall, our model-based simulations showed that only approximately 50% of long-acting rilpivirine C<sub>trough</sub> would be above the 50&#160;ng/mL threshold associated with optimal therapeutic response, while approximately 85% of C<sub>trough</sub> would be above the first quartile of concentrations observed in Phase III trials (32&#160;ng/mL).</p></sec></abstract><kwd-group><kwd>rilpivirine</kwd><kwd>population pharmacokinetics</kwd><kwd>HIV</kwd><kwd>NONMEM</kwd><kwd>long-acting injectable</kwd></kwd-group><funding-group><award-group><funding-source id="cn001"><institution-wrap><institution>Schweizerischer Nationalfonds zur F&#246;rderung der Wissenschaftlichen Forschung
</institution><institution-id institution-id-type="doi">10.13039/501100001711</institution-id></institution-wrap></funding-source></award-group><funding-statement>The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This independent work was funded by the Swiss National Science Foundation, grant number N<sup>&#9702;</sup> 324730_192449. This study was performed within the framework of the Swiss HIV Cohort Study, supported by the Swiss National Science Foundation (grant #201369), by SHCS project #879, and by the SHCS research foundation. The public funding source of the study had no role in the design of the study, in data collection, analysis, and interpretation, in manuscript writing, or in the decision to submit the article for publication. This study received no support from pharmaceutical industries.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Pharmacology of Infectious Diseases</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>1 Introduction</title><p>Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) prescribed orally in combination with emtricitabine and tenofovir in treatment-na&#239;ve patients with a viral load below 100,000 copies at baseline (<xref rid="B35" ref-type="bibr">U.S. Food and Drug Administration, 2011</xref>). In addition, rilpivirine, in combination with dolutegravir, is usually prescribed as a complete regimen for people whose viral load has remained below 50 copies/mL for at least 3&#160;months (<xref rid="B36" ref-type="bibr">U.S. Food and Drug Administration, 2021</xref>). Recently, rilpivirine was formulated as a nanosuspension for intramuscular (i.m.) injection, which allowed the apparent elimination half-life (t<sub>1/2</sub>) of rilpivirine to be extended from 45&#160;h to approximately 13&#8211;28 weeks (<xref rid="B14" ref-type="bibr">Hodge et al., 2021</xref>; <xref rid="B34" ref-type="bibr">U.S. Food and Drug Administration, 2022</xref>; <xref rid="B12" ref-type="bibr">European Medicines Agency (EMA), 2021a</xref>). Rilpivirine in combination with cabotegravir is the first long-acting regimen for the maintenance treatment of HIV-1 infection in adults (<xref rid="B34" ref-type="bibr">U.S. Food and Drug Administration, 2022</xref>; <xref rid="B12" ref-type="bibr">European Medicines Agency (EMA), 2021a</xref>; <xref rid="B13" ref-type="bibr">European Medicines Agency (EMA), 2021b</xref>). Following an oral initiation period, an i.m. injection of 900&#160;mg of rilpivirine <italic toggle="yes">plus</italic> 600&#160;mg of cabotegravir is administered into the gluteal muscle. Subsequently, 900&#160;mg of rilpivirine <italic toggle="yes">plus</italic> 600&#160;mg of cabotegravir is given i.m. every 2&#160;months, or monthly in some regions with 600&#160;mg of rilpivirine <italic toggle="yes">plus</italic> 400&#160;mg of cabotegravir.</p><p>Population pharmacokinetic (popPK) analysis of long-acting rilpivirine based on data from Phase III registrational trials suggested a one-compartmental model with linear elimination and two parallel sequential zero-first-order absorption pathways to describe the drug pharmacokinetics (<xref rid="B22" ref-type="bibr">Neyens et al., 2021</xref>; <xref rid="B2" ref-type="bibr">Benaboud et al., 2023</xref>). The analysis showed that rilpivirine concentrations following i.m. injection and oral administration were similar. In addition, no demographic or clinical covariates were found to significantly impact rilpivirine pharmacokinetics. Regarding therapeutic plasma exposure, the protein-adjusted concentration required for 90% inhibition of viral replication (PAIC<sub>90</sub>) with rilpivirine is 12&#160;ng/mL (<xref rid="B19" ref-type="bibr">Margolis et al., 2015</xref>). However, the clinical target thresholds are higher based on available drug exposure&#8211;response studies. A threshold of 50&#160;ng/mL has been recommended as the minimum concentration to increase the likelihood of a therapeutic response (<xref rid="B1" ref-type="bibr">Aouri et al., 2016</xref>; <xref rid="B10" ref-type="bibr">Dickinson et al., 2015</xref>). Some authors concluded that even higher plasma levels of rilpivirine of up to 100&#160;ng/mL should be targeted (<xref rid="B21" ref-type="bibr">N&#233;ant et al., 2019</xref>). Finally, multivariable analyses showed that rilpivirine resistance mutations at baseline, HIV-1 subtype A6/A1, body mass index (BMI) greater than 30&#160;kg/m<sup>2</sup>, or low rilpivirine and/or cabotegravir trough concentration (C<sub>trough</sub>) 4&#160;weeks after the initial loading dose (i.e., 32&#160;ng/mL and 1,120&#160;ng/mL, respectively, corresponding to the first quartile of concentrations observed in Phase III trials) were associated with an increased risk of virologic failure (<xref rid="B12" ref-type="bibr">European Medicines Agency (EMA), 2021a</xref>; <xref rid="B13" ref-type="bibr">European Medicines Agency (EMA), 2021b</xref>; <xref rid="B9" ref-type="bibr">Cutrell et al., 2021</xref>; <xref rid="B24" ref-type="bibr">Orkin et al., 2023</xref>).</p><p>This popPK analysis is part of a Swiss observational study designed to monitor drug levels in people with HIV (PWH) who are treated with long-acting injectable cabotegravir <italic toggle="yes">plus</italic> rilpivirine (<xref rid="B32" ref-type="bibr">Thoueille et al., 2024a</xref>). The present study provides the first description of long-acting rilpivirine concentration&#8211;time profiles and their variability in PWH in a routine clinical setting and aims to establish percentile curves to help with the interpretation of drug concentration measurements as part of therapeutic drug monitoring (<xref rid="B31" ref-type="bibr">Thoueille et al., 2024b</xref>). Cabotegravir reference curves are described in a separate article for clarity (<xref rid="B33" ref-type="bibr">Thoueille et al., 2024c</xref>).</p></sec><sec sec-type="methods" id="s2"><title>2 Methods</title><sec id="s2-1"><title>2.1 Study population</title><p>The Swiss HIV Cohort Study (SHCS) was established in 1988 and is a prospective longitudinal study for the follow-up of PWH (&gt;18 years old) in Switzerland (<xref rid="B29" ref-type="bibr">Scherrer et al., 2022</xref>). Written informed consent was obtained from all participants, and the SHCS was approved by Canton Ethics Committees. The majority of drug samples were collected at the discretion of physicians longitudinally (i.e., sparse samples) from March 2022 to June 2023, following the approval of long-acting cabotegravir <italic toggle="yes">plus</italic> rilpivirine in Switzerland. All PWH enrolled in the nationwide observational study were considered for the popPK analysis (<xref rid="B32" ref-type="bibr">Thoueille et al., 2024a</xref>). In addition, a detailed sampling plan within a dosing interval was offered to consenting PWH followed-up in Lausanne and Geneva (Switzerland) receiving long-acting rilpivirine. This substudy consisted of blood sampling taken before the dose injections and at 1 week, 2 weeks, 4 weeks, and 8 weeks (corresponding to the end of the dosing interval, C<sub>trough</sub>) after the i.m. dose (Project-ID 2022-00619, approved by the Canton&#8217;s Ethics Committee, Lausanne, Switzerland).</p><p>The dose of rilpivirine, timing of the blood sampling and the last dose, bodyweight (BW), height, and body mass index (BMI) were recorded. Additional clinical and demographic information, such as sex at birth, age, viremia, CD4 cell count, and co-medications were extracted from the SHCS database. The criteria for exclusion from our popPK analysis included one undetectable rilpivirine plasma concentration after oral administration, which was due to non-adherence to oral treatment. In addition, observations were excluded if there was unreliable information about the time and/or date of the last drug administration and/or blood collection.</p></sec><sec id="s2-2"><title>2.2 Analytical method</title><p>Samples were analyzed by a previously published validated multiplex high-performance liquid chromatography coupled to tandem mass spectrometry with a lower limit of quantification of 5&#160;ng/mL (<xref rid="B8" ref-type="bibr">Courlet et al., 2020</xref>).</p></sec><sec id="s2-3"><title>2.3 Population pharmacokinetic analysis</title><p>The non-linear mixed effects modeling was performed using the software NONMEM<sup>&#174;</sup> (v7.5.1, ICON Development Solutions, Ellicott City, MD, USA), assisted by PsN (v5.3.1) and Pirana (v2.9.3). Data management, visual exploration, and statistical analyses were performed using R (v4.1.1, R Development Core Team, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.r-project.org/" ext-link-type="uri">http://www.r-project.org/</ext-link>). As samples were collected at least 2&#160;weeks after treatment initiation, steady-state levels were assumed for all samples collected during the oral lead-in period (i.e., oral rilpivirine half-life (t<sub>1/2</sub>) of 45&#8211;50&#160;h) (<xref rid="B27" ref-type="bibr">Rilpivirine (oral) PK Fact Sheet, 2021</xref>). It should be noted that most PWH contributed to only one sample for oral rilpivirine, as samples were conveniently collected immediately before the i.m. loading dose (i.e., few samples were collected after oral administration). Regarding i.m. injections, steady-state levels were assumed from week 96 in accordance with available information (<xref rid="B25" ref-type="bibr">Overton et al., 2023</xref>). Two PWH received long-acting cabotegravir and rilpivirine every 4 weeks (400&#160;mg/600&#160;mg) for compassionate use before Swiss market authorization. This was the only recommended regimen at that time. These PWH were switched to the two-monthly regimen (600&#160;mg/900&#160;mg of cabotegravir/rilpivirine) a few months after the start of the study.</p></sec><sec id="s2-4"><title>2.4 Model building and selection</title><p>A classic stepwise procedure was used to identify the model that best fitted the concentrations of rilpivirine after oral and i.m. administrations. The models were specified through differential equations using the NONMEM<sup>&#174;</sup> subroutine ADVAN13 to best depict the dynamics of the longitudinal data collected. One- and two-compartment models with different absorption processes and linear elimination were compared. During preliminary model developments, the use of a zero-order absorption (<inline-formula id="inf1">
<mml:math id="m1" overflow="scroll"><mml:mrow><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula>), rather than a first-order absorption, was found to best describe the concentrations after oral administration. However, because of the limited number of samples collected right after drug oral intake, <inline-formula id="inf2">
<mml:math id="m2" overflow="scroll"><mml:mrow><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula> was fixed to 4&#160;h in accordance with available information and our preliminary estimation (<xref rid="B35" ref-type="bibr">U.S. Food and Drug Administration, 2011</xref>; <xref rid="B1" ref-type="bibr">Aouri et al., 2016</xref>). Between-subject variability (BSV) was sequentially tested on all the parameters, which were assumed to follow log-normal distributions.</p><p>The absorption process of long-acting rilpivirine was best described by a parallel first-order absorption (<inline-formula id="inf3">
<mml:math id="m3" overflow="scroll"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:msub><mml:mi>a</mml:mi><mml:mrow><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:msub></mml:mrow></mml:math>
</inline-formula> and <inline-formula id="inf4">
<mml:math id="m4" overflow="scroll"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:msub><mml:mi>a</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>w</mml:mi></mml:mrow></mml:msub></mml:msub></mml:mrow></mml:math>
</inline-formula>), with a fraction of the dose (<inline-formula id="inf5">
<mml:math id="m5" overflow="scroll"><mml:mrow><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>.</mml:mo><mml:mi>m</mml:mi><mml:mo>.</mml:mo><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula>) released via a relatively fast absorption pathway constrained between 0 and 1 using the following equation (<xref rid="B6" ref-type="bibr">Bouzom et al., 2000</xref>):<disp-formula id="equ1"><mml:math id="m6" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mi>E</mml:mi><mml:mi>M</mml:mi><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mi mathvariant="italic">Ln</mml:mi><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mfrac><mml:msub><mml:mi>&#952;</mml:mi><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>.</mml:mo><mml:mi>m</mml:mi><mml:mo>.</mml:mo><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:msub><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>&#952;</mml:mi><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>.</mml:mo><mml:mi>m</mml:mi><mml:mo>.</mml:mo><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced></mml:mrow><mml:mo/></mml:mrow></mml:math></disp-formula>
<disp-formula id="equ2"><mml:math id="m7" overflow="scroll"><mml:mrow><mml:msub><mml:mi>F</mml:mi><mml:msub><mml:mrow><mml:mi>i</mml:mi><mml:mo>.</mml:mo><mml:mi>m</mml:mi><mml:mo>.</mml:mo><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>exp</mml:mi><mml:mtext>&#8201;</mml:mtext><mml:mrow><mml:mfenced open="(" close=")" separators="|"><mml:mrow><mml:mi>T</mml:mi><mml:mi>E</mml:mi><mml:mi>M</mml:mi><mml:mi>P</mml:mi><mml:mo>+</mml:mo><mml:msubsup><mml:mi>&#951;</mml:mi><mml:mi>i</mml:mi><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>.</mml:mo><mml:mi>m</mml:mi><mml:mo>.</mml:mo><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:msubsup></mml:mrow></mml:mfenced></mml:mrow></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>exp</mml:mi><mml:mtext>&#8201;</mml:mtext><mml:mrow><mml:mfenced open="(" close=")" separators="|"><mml:mrow><mml:mi>T</mml:mi><mml:mi>E</mml:mi><mml:mi>M</mml:mi><mml:mi>P</mml:mi><mml:mo>+</mml:mo><mml:msubsup><mml:mi>&#951;</mml:mi><mml:mi>i</mml:mi><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>.</mml:mo><mml:mi>m</mml:mi><mml:mo>.</mml:mo><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:msubsup></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mfrac><mml:mo/></mml:mrow></mml:math></disp-formula>where <inline-formula id="inf6">
<mml:math id="m8" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mi>E</mml:mi><mml:mi>M</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:math>
</inline-formula> is a temporary variable allowing estimation of <inline-formula id="inf7">
<mml:math id="m9" overflow="scroll"><mml:mrow><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>.</mml:mo><mml:mi>m</mml:mi><mml:mo>.</mml:mo><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula>, <inline-formula id="inf8">
<mml:math id="m10" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#952;</mml:mi><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>.</mml:mo><mml:mi>m</mml:mi><mml:mo>.</mml:mo><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:msub></mml:mrow></mml:math>
</inline-formula> is the typical value of <inline-formula id="inf9">
<mml:math id="m11" overflow="scroll"><mml:mrow><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>.</mml:mo><mml:mi>m</mml:mi><mml:mo>.</mml:mo><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula> in our population, <inline-formula id="inf10">
<mml:math id="m12" overflow="scroll"><mml:mrow><mml:msub><mml:mi>F</mml:mi><mml:msub><mml:mrow><mml:mi>i</mml:mi><mml:mo>.</mml:mo><mml:mi>m</mml:mi><mml:mo>.</mml:mo><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub></mml:msub></mml:mrow></mml:math>
</inline-formula> is the estimated <inline-formula id="inf11">
<mml:math id="m13" overflow="scroll"><mml:mrow><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>.</mml:mo><mml:mi>m</mml:mi><mml:mo>.</mml:mo><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula> in the <italic toggle="yes">i</italic>
<sup>th</sup> individual, and <inline-formula id="inf12">
<mml:math id="m14" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>&#951;</mml:mi><mml:mi>i</mml:mi><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>.</mml:mo><mml:mi>m</mml:mi><mml:mo>.</mml:mo><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:msubsup></mml:mrow></mml:math>
</inline-formula> corresponds to the BSV term. The remaining fraction of the dose was released via a slow absorption pathway (<inline-formula id="inf13">
<mml:math id="m15" overflow="scroll"><mml:mrow><mml:msub><mml:mi>F</mml:mi><mml:msub><mml:mrow><mml:mi>i</mml:mi><mml:mo>.</mml:mo><mml:mi>m</mml:mi><mml:mo>.</mml:mo><mml:mi>s</mml:mi><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>w</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:msub><mml:mrow><mml:mi>i</mml:mi><mml:mo>.</mml:mo><mml:mi>m</mml:mi><mml:mo>.</mml:mo><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub></mml:msub></mml:mrow></mml:math>
</inline-formula>). In order to account for within-subject variability between injections (such as unexplained physiological differences or injection-related variability), inter-occasion variability (IOV) was also considered. In particular, occasions were coded to be consistent with the duration of the follow-up by including an &#8220;occasion&#8221; variable constructed with an incremental number within each subject for a maximum of six occasions/injections. Lastly, common and distinct residual unexplained variabilities (RUV) were evaluated for oral and i.m. administration. The following covariates were tested for significance on the base model parameters using linear functions: sex at birth, age, ethnicity, BW, BMI, and eGFR categories [classified according to the CKD-EPI equations (<xref rid="B17" ref-type="bibr">Levey et al., 2009</xref>)]. BW and BMI were also evaluated using allometric scaling relationships to estimate the allometric exponent. No clinically relevant concomitant drugs, such as potent 3A4 inducers, were encountered in the study population (<xref rid="B12" ref-type="bibr">European Medicines Agency (EMA), 2021a</xref>).</p><p>The variation of the NONMEM<sup>&#174;</sup> objective function value (&#916;OFV) was used at a 0.05 significance level in the forward model-building step (&#916;OFV &lt; &#8722;3.84 for one additional parameter) to statistically discriminate hierarchical models. During the backward deletion step, a significance level of 0.01 (&#916;OFV &gt;6.63 for the removal of one parameter) was used. Non-nested models were discriminated using Akaike&#8217;s information criterion. Model selection relied on diagnostic plots and the accuracy of PK parameter estimates, quantified by the relative standard error (RSE). The reliability of the results was also assessed by characterizing model shrinkage and the normality of the distribution of individual eta estimates.</p></sec><sec id="s2-5"><title>2.5 Model-based Monte Carlo simulations</title><p>The clinical relevance of covariates was evaluated by comparing the PK profiles and C<sub>trough</sub> values of rilpivirine obtained in different groups of interest. Population percentiles for rilpivirine after oral and i.m. administration were generated to help interpret drug concentration measurements as part of therapeutic drug monitoring.</p></sec><sec id="s2-6"><title>2.6 Model validation</title><p>The observed concentrations were compared with the 5th, 50th, and 95th prediction percentiles using prediction-corrected visual predictive checks (pcVPCs) performed on the final popPK model (<xref rid="B18" ref-type="bibr">Lindbom et al., 2005</xref>; <xref rid="B3" ref-type="bibr">Bergstrand et al., 2011</xref>; <xref rid="B15" ref-type="bibr">Jonsson and Karlsson, 1999</xref>). In addition, the original model estimates were examined against the bootstrap median parameter values and their 95% confidence intervals generated using 2000 replicates (<xref rid="B18" ref-type="bibr">Lindbom et al., 2005</xref>). Finally, cross-validation was performed using repeated data-splitting (n = 5) to create random subsets of the dataset, with 80% allocated to the modeling dataset and 20% to the validation dataset. Log-transformed individual observed and predicted concentrations were then evaluated using mean prediction error (MPE) and root mean square error (RMSE) as metrics to assess model accuracy and precision, respectively (<xref rid="B30" ref-type="bibr">Sheiner and Beal, 1981</xref>).</p></sec></sec><sec sec-type="results" id="s3"><title>3 Results</title><p>Overall, 238 PWH contributed to 1,038 rilpivirine concentrations (186 concentrations after oral administration and 852 concentrations after i.m. injection collected from 176&#160;PWH and 222 PWH, respectively), with detailed PK investigation performed on 28 PWH. <xref rid="T1" ref-type="table">Table 1</xref> summarizes the characteristics of the PWH included in the analysis. Overall, four samples (range: 1&#8211;15) were collected per individual, with one (1&#8211;3) for oral rilpivirine and three (1&#8211;14) for i.m. rilpivirine. The median duration of follow-up was 26 weeks (3&#8211;196). Only 10 PWH had rilpivirine concentrations assumed to be at a steady state (i.e., from week 96) after i.m. administration.</p><table-wrap position="float" id="T1" orientation="portrait"><label>TABLE 1</label><caption><p>Characteristics of the PWH.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="center" rowspan="1" colspan="1">Population characteristics<break/>Last recorded value</th><th align="center" rowspan="1" colspan="1">Median (range) or n (%)</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">Sex<break/>&#8195;Male<break/>&#8195;Female</td><td align="left" rowspan="1" colspan="1">
<break/>190 (80)<break/>48 (20)</td></tr><tr><td align="left" rowspan="1" colspan="1">Age, years</td><td align="left" rowspan="1" colspan="1">46 (20&#8211;79)</td></tr><tr><td align="left" rowspan="1" colspan="1">Ethnicity<break/>&#8195;White<break/>&#8195;Black<break/>&#8195;Hispanic American<break/>&#8195;Asian<break/>&#8195;Other/Missing</td><td align="left" rowspan="1" colspan="1">
<break/>133 (56)<break/>36 (15)<break/>19 (8)<break/>11 (5)<break/>39 (16)</td></tr><tr><td align="left" rowspan="1" colspan="1">Body weight, kg</td><td align="left" rowspan="1" colspan="1">78 (50&#8211;126)</td></tr><tr><td align="left" rowspan="1" colspan="1">Height, cm</td><td align="left" rowspan="1" colspan="1">176 (151&#8211;198)</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup>
<break/>&#8195;&lt; 25<break/>&#8195;25&#8211;30<break/>&#8195;&gt;30</td><td align="left" rowspan="1" colspan="1">25.4 (18.2&#8211;43.3)<break/>104 (44)<break/>103 (43)<break/>31 (13)</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR<xref rid="Tfn1" ref-type="table-fn">
<sup>a</sup>
</xref>, mL/min/1.73&#160;m<sup>2</sup> (<xref rid="B17" ref-type="bibr">Levey et al., 2009</xref>)<break/>&#8195;G1: &#8805;90<break/>&#8195;G2: 60&#8211;89<break/>&#8195;G3: 30&#8211;59</td><td align="left" rowspan="1" colspan="1">
<break/>158 (66)<break/>76 (32)<break/>4 (2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Liver cirrhosis<xref rid="Tfn1" ref-type="table-fn">
<sup>a</sup>
</xref>, Child&#8211;Pugh score (<xref rid="B7" ref-type="bibr">Child and Turcotte, 1964</xref>)<break/>&#8195;No<break/>&#8195;Class A</td><td align="left" rowspan="1" colspan="1">
<break/>
<break/>236 (99)<break/>2 (1)</td></tr><tr><td align="left" rowspan="1" colspan="1">CD4 cell count, cells/mm<sup>3</sup>
<break/>&#8195;&#8805; 500<break/>&#8195;350 to &lt;500<break/>&#8195;&lt;350</td><td align="left" rowspan="1" colspan="1">
<break/>186 (78)<break/>23 (10)<break/>29 (12)</td></tr><tr><td align="left" rowspan="1" colspan="1">Plasma HIV RNA, copies/mL<break/>&#8195;&lt; 50<break/>&#8195;&#8805; 50 and &lt; 200<break/>&#8195;&#8805; 200</td><td align="left" rowspan="1" colspan="1">
<break/>233 (98)<break/>4 (2)<break/>1 (&lt;1)</td></tr></tbody></table><table-wrap-foot><fn><p>BMI, body mass index; eGFR: estimated glomerular filtration rate, calculated according to the CKD-EPI equations reported by <xref rid="B17" ref-type="bibr">Levey et al. (2009)</xref>.</p></fn><fn id="Tfn1"><label>
<sup>a</sup>
</label><p>&#8804;2% missing information.</p></fn></table-wrap-foot></table-wrap><sec id="s3-1"><title>3.1 Structural and covariate models</title><p>Consistent with available information (<xref rid="B22" ref-type="bibr">Neyens et al., 2021</xref>), long-acting rilpivirine was characterized by &#8220;flip-flop&#8221; kinetics (i.e., absorption rate constants (<inline-formula id="inf14">
<mml:math id="m16" overflow="scroll"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:msub><mml:mi>a</mml:mi><mml:mrow><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:msub></mml:mrow></mml:math>
</inline-formula> and <inline-formula id="inf15">
<mml:math id="m17" overflow="scroll"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:msub><mml:mi>a</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>w</mml:mi></mml:mrow></mml:msub></mml:msub></mml:mrow></mml:math>
</inline-formula>) lower than elimination rate constant (<inline-formula id="inf16">
<mml:math id="m18" overflow="scroll"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mi>e</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mi>C</mml:mi><mml:mi>L</mml:mi><mml:mo>/</mml:mo><mml:mi>V</mml:mi></mml:mrow></mml:math>
</inline-formula>)). <xref rid="F1" ref-type="fig">Figure 1</xref> presents the structural model that best described rilpivirine concentrations. The absorption process of long-acting rilpivirine was best described by a parallel first-order absorption (&#916;OFV = &#8722;192, <italic toggle="yes">p</italic> &lt; 0.001, compared to the model with a single first-order absorption). On the other hand, a zero-order absorption process (<inline-formula id="inf17">
<mml:math id="m19" overflow="scroll"><mml:mrow><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula>, fixed to literature value) was retained for oral administration, with the inclusion of a relative bioavailability (<inline-formula id="inf18">
<mml:math id="m20" overflow="scroll"><mml:mrow><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula>) (i.e., as i.m. administration was assumed to be 100% bioavailable) with BSV (&#916;OFV = &#8722;15, <italic toggle="yes">p</italic> &lt; 0.001). In addition, it was found that a two-compartment model (with <inline-formula id="inf19">
<mml:math id="m21" overflow="scroll"><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mn>3</mml:mn></mml:msub></mml:mrow></mml:math>
</inline-formula> and <inline-formula id="inf20">
<mml:math id="m22" overflow="scroll"><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mn>4</mml:mn></mml:msub></mml:mrow></mml:math>
</inline-formula> volumes of distribution of the central and peripheral compartments, respectively) provided the best description of the data (&#916;OFV = &#8722;20, <italic toggle="yes">p</italic> &lt; 0.001). The assignment of BSV on <inline-formula id="inf21">
<mml:math id="m23" overflow="scroll"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:msub><mml:mi>a</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>w</mml:mi></mml:mrow></mml:msub></mml:msub></mml:mrow></mml:math>
</inline-formula> significantly improved data description (&#916;OFV = &#8722;48, <italic toggle="yes">p</italic> &lt; 0.001), while the IOV after i.m. administration was supported for clearance (<inline-formula id="inf22">
<mml:math id="m24" overflow="scroll"><mml:mrow><mml:mi>C</mml:mi><mml:mi>L</mml:mi></mml:mrow></mml:math>
</inline-formula>) (&#916;OFV = &#8722;32, <italic toggle="yes">p</italic> &lt; 0.001). Importantly, we investigated the inclusion of IOV in the absorption process of i.m. rilpivirine. However, such variability could not be retained in the absorption parameters due to model stability and statistical significance. Finally, a common mixed error model for both routes of administration failed to estimate both components of the error model. An additive error model best described rilpivirine RUV after oral administration, while a proportional error model was retained for rilpivirine RUV when administered i.m. Parameter estimates of the base popPK model with BSV (CV%) were: a <inline-formula id="inf23">
<mml:math id="m25" overflow="scroll"><mml:mrow><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula> of 4&#160;h (fixed), an <inline-formula id="inf24">
<mml:math id="m26" overflow="scroll"><mml:mrow><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula> of 65.4% (37.1%), a <inline-formula id="inf25">
<mml:math id="m27" overflow="scroll"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:msub><mml:mi>a</mml:mi><mml:mrow><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:msub></mml:mrow></mml:math>
</inline-formula> of 0.00214 h<sup>&#8722;1</sup> with an <inline-formula id="inf26">
<mml:math id="m28" overflow="scroll"><mml:mrow><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>.</mml:mo><mml:mi>m</mml:mi><mml:mo>.</mml:mo><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula> of 27.6% (16.8%), a <inline-formula id="inf27">
<mml:math id="m29" overflow="scroll"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:msub><mml:mi>a</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>w</mml:mi></mml:mrow></mml:msub></mml:msub></mml:mrow></mml:math>
</inline-formula> of 0.000229 h<sup>&#8722;1</sup> (82.7%), a <inline-formula id="inf28">
<mml:math id="m30" overflow="scroll"><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mn>3</mml:mn></mml:msub></mml:mrow></mml:math>
</inline-formula> of 277&#160;L, an inter-compartment clearance (<inline-formula id="inf29">
<mml:math id="m31" overflow="scroll"><mml:mrow><mml:mi>Q</mml:mi></mml:mrow></mml:math>
</inline-formula>) of 4.08&#160;L/h, a <inline-formula id="inf30">
<mml:math id="m32" overflow="scroll"><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mn>4</mml:mn></mml:msub></mml:mrow></mml:math>
</inline-formula> of 839&#160;L, and a <inline-formula id="inf31">
<mml:math id="m33" overflow="scroll"><mml:mrow><mml:mi>C</mml:mi><mml:mi>L</mml:mi></mml:mrow></mml:math>
</inline-formula> of 6.74&#160;L/h (25.9%) with an IOV of 13%.</p><fig position="float" id="F1" orientation="portrait"><label>FIGURE 1</label><caption><p>Structural model used to describe rilpivirine concentration-time profile. i.m.: intramuscular; <inline-formula id="inf32">
<mml:math id="m34" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="bold-italic">F</mml:mi><mml:mrow><mml:mi mathvariant="bold-italic">o</mml:mi><mml:mi mathvariant="bold-italic">r</mml:mi><mml:mi mathvariant="bold-italic">a</mml:mi><mml:mi mathvariant="bold-italic">l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula>: absolute bioavailability of oral to i.m. administrations; <inline-formula id="inf33">
<mml:math id="m35" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="bold-italic">D</mml:mi><mml:mrow><mml:mi mathvariant="bold-italic">o</mml:mi><mml:mi mathvariant="bold-italic">r</mml:mi><mml:mi mathvariant="bold-italic">a</mml:mi><mml:mi mathvariant="bold-italic">l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula>: zero-order absorption time for oral administration; <inline-formula id="inf34">
<mml:math id="m36" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="bold-italic">F</mml:mi><mml:mrow><mml:mi mathvariant="bold-italic">i</mml:mi><mml:mo>.</mml:mo><mml:mi mathvariant="bold-italic">m</mml:mi><mml:mo>.</mml:mo><mml:mi mathvariant="bold-italic">f</mml:mi><mml:mi mathvariant="bold-italic">a</mml:mi><mml:mi mathvariant="bold-italic">s</mml:mi><mml:mi mathvariant="bold-italic">t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula>: fraction for the fast absorption pathway after i.m. administration; <inline-formula id="inf35">
<mml:math id="m37" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="bold-italic">k</mml:mi><mml:msub><mml:mi mathvariant="bold-italic">a</mml:mi><mml:mrow><mml:mi mathvariant="bold-italic">f</mml:mi><mml:mi mathvariant="bold-italic">a</mml:mi><mml:mi mathvariant="bold-italic">s</mml:mi><mml:mi mathvariant="bold-italic">t</mml:mi></mml:mrow></mml:msub></mml:msub></mml:mrow></mml:math>
</inline-formula> and <inline-formula id="inf36">
<mml:math id="m38" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="bold-italic">k</mml:mi><mml:msub><mml:mi mathvariant="bold-italic">a</mml:mi><mml:mrow><mml:mi mathvariant="bold-italic">s</mml:mi><mml:mi mathvariant="bold-italic">l</mml:mi><mml:mi mathvariant="bold-italic">o</mml:mi><mml:mi mathvariant="bold-italic">w</mml:mi></mml:mrow></mml:msub></mml:msub></mml:mrow></mml:math>
</inline-formula>: fast and slow first-order absorption rate constants for i.m. administration, respectively; <inline-formula id="inf37">
<mml:math id="m39" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="bold-italic">V</mml:mi><mml:mn mathvariant="bold">3</mml:mn></mml:msub></mml:mrow></mml:math>
</inline-formula>: apparent central volume of distribution; <inline-formula id="inf38">
<mml:math id="m40" overflow="scroll"><mml:mrow><mml:mi mathvariant="bold-italic">Q</mml:mi></mml:mrow></mml:math>
</inline-formula>: apparent intercompartmental clearance; <inline-formula id="inf39">
<mml:math id="m41" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="bold-italic">V</mml:mi><mml:mn mathvariant="bold">4</mml:mn></mml:msub></mml:mrow></mml:math>
</inline-formula>: apparent peripheral volume of distribution; <inline-formula id="inf40">
<mml:math id="m42" overflow="scroll"><mml:mrow><mml:mi mathvariant="bold-italic">C</mml:mi><mml:mi mathvariant="bold-italic">L</mml:mi></mml:mrow></mml:math>
</inline-formula>: apparent clearance.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-15-1437400-g001.jpg"/></fig><p>Univariate analyses revealed the effects of female sex (&#916;OFV = &#8722;11, <italic toggle="yes">p</italic> &lt; 0.001), and BMI (&#916;OFV = &#8722;6, <italic toggle="yes">p</italic> &lt; 0.05) on <inline-formula id="inf41">
<mml:math id="m43" overflow="scroll"><mml:mrow><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>.</mml:mo><mml:mi>m</mml:mi><mml:mo>.</mml:mo><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula>. After forward insertion (<italic toggle="yes">p</italic> &lt; 0.05) and backward deletion (<italic toggle="yes">p</italic> &lt; 0.01), the model only included the effect of female sex as a percent change on <inline-formula id="inf42">
<mml:math id="m44" overflow="scroll"><mml:mrow><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>.</mml:mo><mml:mi>m</mml:mi><mml:mo>.</mml:mo><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula>:<disp-formula id="equ3"><mml:math id="m45" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mi>E</mml:mi><mml:mi>M</mml:mi><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mi mathvariant="italic">Ln</mml:mi><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mi>&#952;</mml:mi><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>.</mml:mo><mml:mi>m</mml:mi><mml:mo>.</mml:mo><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:msub><mml:mo>&#8901;</mml:mo><mml:mrow><mml:mfenced open="(" close=")" separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>&#952;</mml:mi><mml:mrow><mml:mi>F</mml:mi><mml:mi>e</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>&#952;</mml:mi><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>.</mml:mo><mml:mi>m</mml:mi><mml:mo>.</mml:mo><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:msub><mml:mo>&#8901;</mml:mo><mml:mrow><mml:mfenced open="(" close=")" separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>&#952;</mml:mi><mml:mrow><mml:mi>F</mml:mi><mml:mi>e</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced></mml:mrow><mml:mo/></mml:mrow></mml:math></disp-formula>
</p><p>This effect showed that females had an <inline-formula id="inf43">
<mml:math id="m46" overflow="scroll"><mml:mrow><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>.</mml:mo><mml:mi>m</mml:mi><mml:mo>.</mml:mo><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula> 45.6% lower than males, resulting in a greater proportion of the dose absorbed via the slow absorption pathway. Finally, the sex covariate explained 11% of the BSV on <inline-formula id="inf44">
<mml:math id="m47" overflow="scroll"><mml:mrow><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>.</mml:mo><mml:mi>m</mml:mi><mml:mo>.</mml:mo><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula>.</p></sec><sec id="s3-2"><title>3.2 Model-based Monte Carlo simulations</title><p>
<xref rid="s12" ref-type="sec">Supplementary Figure S2</xref> shows the PK profile with variability obtained for rilpivirine after oral administration. The median C<sub>trough</sub> at a steady state under oral rilpivirine was 80&#160;ng/mL [95% prediction interval (PI<sub>95</sub>): 32&#8211;211]. Our model-based simulations suggest that 85% of PWH receiving oral rilpivirine would have a C<sub>trough</sub> above the target of 50&#160;ng/mL associated with therapeutic response. Regarding long-acting rilpivirine, it was found that females had a 12% lower rilpivirine C<sub>trough</sub> 4&#160;weeks after the loading dose (<xref rid="s12" ref-type="sec">Supplementary Figures S3, S4</xref>; <xref rid="s12" ref-type="sec">Supplementary Table S2</xref>). Then, females had 8%, 12%, 10%, 14%, and 15% higher rilpivirine C<sub>trough</sub> at weeks 16, 24, 32, 40, and 48, respectively. Therefore, although statistically significant, the effect of sex on long-acting rilpivirine C<sub>trough</sub> was not considered clinically relevant, and this model was not validated. Indeed, the base and covariate models showed a maximum difference of 14% in the prediction of i.m. rilpivirine C<sub>trough</sub> (<xref rid="s12" ref-type="sec">Supplementary Table S2</xref>). <xref rid="F2" ref-type="fig">Figure 2</xref> presents the population PK profile obtained for rilpivirine after i.m. injection (i.e., without any covariate). Overall, our model-based simulations showed that only 50% of rilpvirine C<sub>trough</sub> values were above the 50&#160;ng/mL threshold after i.m. injection at week 8 (i.e., 4&#160;weeks after the loading dose). A median 22% reduction in C<sub>trough</sub> values was observed at week 16. Subsequently, rilpivirine C<sub>trough</sub> values were found to increase through week 48 but remained almost 50% below the 50&#160;ng/mL target at all time points. Finally, model-based simulations suggested that approximately 5% and almost 15% of PWH would have C<sub>trough</sub> values below 2&#215;PAIC<sub>90</sub> (i.e., 24&#160;ng/mL) and below the first quartile of concentrations observed in Phase III trials (i.e., 32&#160;ng/mL), respectively.</p><fig position="float" id="F2" orientation="portrait"><label>FIGURE 2</label><caption><p>Simulated population percentiles after intramuscular administration of rilpivirine following a 4-week period of oral lead-in. The solid white lines represent the median (50% percentile), while the dark surfaces encompass the 50% prediction intervals, and the light surfaces encompass the 95% prediction intervals. The horizontal dashed line represents the PAIC<sub>90</sub> of 12&#160;ng/mL, while the dotted line shows the threshold of 50&#160;ng/mL.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-15-1437400-g002.jpg"/></fig></sec><sec id="s3-3"><title>3.3 Model validation</title><p>
<xref rid="s12" ref-type="sec">Supplementary Figure S1</xref> shows the goodness-of-fit diagnostic plots of the base model as no covariates were found to be clinically relevant. It should be noted that there was a modest shrinkage of 40% on the BSV of <inline-formula id="inf45">
<mml:math id="m48" overflow="scroll"><mml:mrow><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>.</mml:mo><mml:mi>m</mml:mi><mml:mo>.</mml:mo><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula>, which could make the use of diagnostic plots of limited value (<xref rid="B28" ref-type="bibr">Savic and Karlsson, 2009</xref>). However, the pcVPC and the bootstrap results, shown in <xref rid="F3" ref-type="fig">Figure 3</xref> and <xref rid="T2" ref-type="table">Table 2</xref>, respectively, support the reliability of the final model (without covariate). Despite a modest model misspecification in the first days of LAI therapy, probably due to the paucity of data at the early stage of treatment, the pcVPC supports the adequacy of the model developed, particularly in predicting the trough concentrations essential for clinical decisions. Finally, cross-validation (<xref rid="s12" ref-type="sec">Supplementary Table S1</xref>) revealed no significant bias (mean MPE = 0.7%, mean 95% confidence interval = &#8722;1.4% to 2.9%) with a precision of 16.8% (range: 14.3%&#8211;19.1%).</p><fig position="float" id="F3" orientation="portrait"><label>FIGURE 3</label><caption><p>Visual predictive check of the retained rilpivirine popPK model for oral administration (left panel) and for intramuscular administration (right panel) for rilpivirine. Open circles represent the observed plasma concentrations. Solid and dashed lines represent the median and 90% prediction intervals (PI<sub>90%</sub>) of the observed data, respectively. Dark- and light-shaded surfaces represent the model-predicted 90% confidence intervals of the simulated median and PI<sub>90%</sub>. Note: one concentration with time beyond 4000&#160;h is not displayed.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-15-1437400-g003.jpg"/></fig><table-wrap position="float" id="T2" orientation="portrait"><label>TABLE 2</label><caption><p>Final population PK parameter estimates of rilpivirine with their bootstrap evaluations.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th rowspan="2" align="left" colspan="1">Parameters</th><th align="left" rowspan="1" colspan="1">Final model</th><th align="left" rowspan="1" colspan="1">Bootstrap (n = 2000)</th></tr><tr><th align="left" rowspan="1" colspan="1">Estimate (RSE, %)<xref rid="Tfn3" ref-type="table-fn">
<sup>b</sup>
</xref>
</th><th align="left" rowspan="1" colspan="1">Median [CI<sub>95%</sub>]</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="inf46">
<mml:math id="m49" overflow="scroll"><mml:mrow><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula> (%)</td><td align="left" rowspan="1" colspan="1">65.4 (5)</td><td align="left" rowspan="1" colspan="1">64.8 [52.6&#8211;73.3]</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="inf47">
<mml:math id="m50" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#969;</mml:mi><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:msub></mml:mrow></mml:math>
</inline-formula> (CV%<xref rid="Tfn2" ref-type="table-fn">
<sup>a</sup>
</xref>)</td><td align="left" rowspan="1" colspan="1">37.1 (11)</td><td align="left" rowspan="1" colspan="1">36.8 [24.5&#8211;46.3]</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="inf48">
<mml:math id="m51" overflow="scroll"><mml:mrow><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula> (h)</td><td align="left" rowspan="1" colspan="1">4 FIX</td><td align="left" rowspan="1" colspan="1">4 FIX</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="inf49">
<mml:math id="m52" overflow="scroll"><mml:mrow><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>.</mml:mo><mml:mi>m</mml:mi><mml:mo>.</mml:mo><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula> (%)</td><td align="left" rowspan="1" colspan="1">27.6 (9)</td><td align="left" rowspan="1" colspan="1">27.5 [22.5&#8211;32.4]</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="inf50">
<mml:math id="m53" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#969;</mml:mi><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>.</mml:mo><mml:mi>m</mml:mi><mml:mo>.</mml:mo><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:msub></mml:mrow></mml:math>
</inline-formula> (CV%<xref rid="Tfn4" ref-type="table-fn">
<sup>c</sup>
</xref>)</td><td align="left" rowspan="1" colspan="1">16.8 (15) <xref rid="Tfn5" ref-type="table-fn">
<sup>d</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">16.7 [10.0&#8211;25.3]</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="inf51">
<mml:math id="m54" overflow="scroll"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:msub><mml:mi>a</mml:mi><mml:mrow><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:msub></mml:mrow></mml:math>
</inline-formula> (h<sup>&#8722;1</sup>)</td><td align="left" rowspan="1" colspan="1">0.00214 (11)</td><td align="left" rowspan="1" colspan="1">0.00211 [0.00167&#8211;0.00266]</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="inf52">
<mml:math id="m55" overflow="scroll"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:msub><mml:mi>a</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>w</mml:mi></mml:mrow></mml:msub></mml:msub></mml:mrow></mml:math>
</inline-formula> (h<sup>&#8722;1</sup>)</td><td align="left" rowspan="1" colspan="1">0.000229 (11)</td><td align="left" rowspan="1" colspan="1">0.000225 [0.000108&#8211;0.000292]</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="inf53">
<mml:math id="m56" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#969;</mml:mi><mml:msub><mml:mi>k</mml:mi><mml:msub><mml:mi>a</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>w</mml:mi></mml:mrow></mml:msub></mml:msub></mml:msub></mml:mrow></mml:math>
</inline-formula> (CV%<xref rid="Tfn2" ref-type="table-fn">
<sup>a</sup>
</xref>)</td><td align="left" rowspan="1" colspan="1">82.7 (12)</td><td align="left" rowspan="1" colspan="1">80.6 [51.5&#8211;106.0]</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="inf54">
<mml:math id="m57" overflow="scroll"><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mn>3</mml:mn></mml:msub></mml:mrow></mml:math>
</inline-formula> (L)</td><td align="left" rowspan="1" colspan="1">277 (25)</td><td align="left" rowspan="1" colspan="1">274 [184&#8211;433]</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="inf55">
<mml:math id="m58" overflow="scroll"><mml:mrow><mml:mi>Q</mml:mi></mml:mrow></mml:math>
</inline-formula> (L/h)</td><td align="left" rowspan="1" colspan="1">4.08 (40)</td><td align="left" rowspan="1" colspan="1">4.03 [1.75&#8211;9.30]</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="inf56">
<mml:math id="m59" overflow="scroll"><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mn>4</mml:mn></mml:msub></mml:mrow></mml:math>
</inline-formula> (L)</td><td align="left" rowspan="1" colspan="1">839 (11)</td><td align="left" rowspan="1" colspan="1">853 [407&#8211;1,365]</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="inf57">
<mml:math id="m60" overflow="scroll"><mml:mrow><mml:mi>C</mml:mi><mml:mi>L</mml:mi></mml:mrow></mml:math>
</inline-formula> (L/h)</td><td align="left" rowspan="1" colspan="1">6.74 (3)</td><td align="left" rowspan="1" colspan="1">6.68 [5.41&#8211;7.37]</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="inf58">
<mml:math id="m61" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#969;</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>L</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula> (CV%<xref rid="Tfn2" ref-type="table-fn">
<sup>a</sup>
</xref>)</td><td align="left" rowspan="1" colspan="1">25.9 (9)</td><td align="left" rowspan="1" colspan="1">25.5 [17.6&#8211;30.3]</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="inf59">
<mml:math id="m62" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#969;</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>O</mml:mi><mml:mi>V</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula> (CV%<xref rid="Tfn2" ref-type="table-fn">
<sup>a</sup>
</xref>)</td><td align="left" rowspan="1" colspan="1">13.0 (10)</td><td align="left" rowspan="1" colspan="1">13.0 [5.35&#8211;17.6]</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="inf60">
<mml:math id="m63" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#963;</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>d</mml:mi><mml:mi>d</mml:mi><mml:mo>&#8722;</mml:mo><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula> (ng/mL)</td><td align="left" rowspan="1" colspan="1">18 (22)</td><td align="left" rowspan="1" colspan="1">17.7 [10.5&#8211;28.1]</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="inf61">
<mml:math id="m64" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#963;</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>p</mml:mi><mml:mo>&#8722;</mml:mo><mml:mi>L</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula> (CV%<xref rid="Tfn2" ref-type="table-fn">
<sup>a</sup>
</xref>)</td><td align="left" rowspan="1" colspan="1">18 (5)</td><td align="left" rowspan="1" colspan="1">17.5 [15.2&#8211;20.1]</td></tr></tbody></table><table-wrap-foot><fn><p>
<inline-formula id="inf62">
<mml:math id="m65" overflow="scroll"><mml:mrow><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula>: typical relative bioavailability of oral to i.m. administration; <inline-formula id="inf63">
<mml:math id="m66" overflow="scroll"><mml:mrow><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula>: typical zero-order absorption time for oral administration; <inline-formula id="inf64">
<mml:math id="m67" overflow="scroll"><mml:mrow><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>.</mml:mo><mml:mi>m</mml:mi><mml:mo>.</mml:mo><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula>: fraction for the fast absorption pathway after intramuscular administration; <inline-formula id="inf65">
<mml:math id="m68" overflow="scroll"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:msub><mml:mi>a</mml:mi><mml:mrow><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:msub></mml:mrow></mml:math>
</inline-formula> and <inline-formula id="inf66">
<mml:math id="m69" overflow="scroll"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:msub><mml:mi>a</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>w</mml:mi></mml:mrow></mml:msub></mml:msub></mml:mrow></mml:math>
</inline-formula>: typical fast and slow first-order absorption rate constants for intramuscular administration, respectively; <inline-formula id="inf67">
<mml:math id="m70" overflow="scroll"><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mn>3</mml:mn></mml:msub></mml:mrow></mml:math>
</inline-formula>: typical apparent central volume of distribution; <inline-formula id="inf68">
<mml:math id="m71" overflow="scroll"><mml:mrow><mml:mi>Q</mml:mi></mml:mrow></mml:math>
</inline-formula>: typical apparent intercompartmental clearance; <inline-formula id="inf69">
<mml:math id="m72" overflow="scroll"><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mn>4</mml:mn></mml:msub></mml:mrow></mml:math>
</inline-formula>: typical apparent peripheral volume of distribution; <inline-formula id="inf70">
<mml:math id="m73" overflow="scroll"><mml:mrow><mml:mi>C</mml:mi><mml:mi>L</mml:mi></mml:mrow></mml:math>
</inline-formula>: typical apparent clearance; <inline-formula id="inf71">
<mml:math id="m74" overflow="scroll"><mml:mrow><mml:mi>&#969;</mml:mi></mml:mrow></mml:math>
</inline-formula>: between-subject variability (BSV); <inline-formula id="inf72">
<mml:math id="m75" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#969;</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>O</mml:mi><mml:mi>V</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula>: inter-occasion variability (IOV); <inline-formula id="inf73">
<mml:math id="m76" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#963;</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>d</mml:mi><mml:mi>d</mml:mi><mml:mo>&#8722;</mml:mo><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula>: additive residual error for oral administration; <inline-formula id="inf74">
<mml:math id="m77" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#963;</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>p</mml:mi><mml:mo>&#8722;</mml:mo><mml:mi>L</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula>: proportional residual error for intramuscular administration.</p></fn><fn id="Tfn2"><label>
<sup>a</sup>
</label><p>Coefficient of variation (CV, %) for BSV was calculated as follows: <inline-formula id="inf75">
<mml:math id="m78" overflow="scroll"><mml:mrow><mml:mi>C</mml:mi><mml:mi>V</mml:mi><mml:mo>=</mml:mo><mml:msqrt><mml:mrow><mml:mfenced open="(" close=")" separators="|"><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:msup><mml:mi>&#969;</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:msup><mml:mo>&#8722;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:msqrt></mml:mrow></mml:math>
</inline-formula>
</p></fn><fn id="Tfn3"><label>
<sup>b</sup>
</label><p>Relative standard error (RSE) of the estimate, expressed as a percentage, with standard error (SE) of estimate, calculated as follows: <inline-formula id="inf76">
<mml:math id="m79" overflow="scroll"><mml:mrow><mml:mi>R</mml:mi><mml:mi>S</mml:mi><mml:mi>E</mml:mi><mml:mtext>&#8201;</mml:mtext><mml:mrow><mml:mfenced open="(" close=")" separators="|"><mml:mrow><mml:mo>%</mml:mo></mml:mrow></mml:mfenced></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:msup><mml:mi>&#969;</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:msup><mml:mo>&#8901;</mml:mo><mml:mi>S</mml:mi><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mo>&#8901;</mml:mo><mml:mrow><mml:mfenced open="(" close=")" separators="|"><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:msup><mml:mi>&#969;</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:msup><mml:mo>&#8722;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:math>
</inline-formula>
</p></fn><fn id="Tfn4"><label>
<sup>c</sup>
</label><p>Coefficient of variation (CV, %) for the BSV of <inline-formula id="inf77">
<mml:math id="m80" overflow="scroll"><mml:mrow><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>.</mml:mo><mml:mi>m</mml:mi><mml:mo>.</mml:mo><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula> was approximated as: <inline-formula id="inf78">
<mml:math id="m81" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi>C</mml:mi><mml:mi>V</mml:mi></mml:mrow><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>.</mml:mo><mml:mi>m</mml:mi><mml:mo>.</mml:mo><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>&#952;</mml:mi><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>.</mml:mo><mml:mi>m</mml:mi><mml:mo>.</mml:mo><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:msub><mml:mo>&#8901;</mml:mo><mml:mrow><mml:mfenced open="(" close=")" separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>&#952;</mml:mi><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>.</mml:mo><mml:mi>m</mml:mi><mml:mo>.</mml:mo><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:msub></mml:mrow></mml:mfenced></mml:mrow><mml:mo>&#8901;</mml:mo><mml:msqrt><mml:msup><mml:mi>&#951;</mml:mi><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>.</mml:mo><mml:mi>m</mml:mi><mml:mo>.</mml:mo><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:msup></mml:msqrt></mml:mrow></mml:math>
</inline-formula>
</p></fn><fn id="Tfn5"><label>
<sup>d</sup>
</label><p>Calculated using the propagation error formula.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" id="s4"><title>4 Discussion</title><p>The present study describes the first popPK model of rilpivirine in PWH followed in a routine clinical setting, including both oral and i.m. routes of administration. The parallel absorption process found in our popPK model for long-acting rilpivirine is consistent with a previously published popPK model based on Phase III registrational studies (<xref rid="B22" ref-type="bibr">Neyens et al., 2021</xref>). Our model shows that approximately a quarter (i.e., 27.6%) of the nanosuspension dose is absorbed via a relatively fast absorption pathway, while the remaining (i.e., 72.4%) is absorbed via a ten-time slower absorption pathway. Females were found to have an almost 50% reduction in the fraction of the dose absorbed via the fast absorption pathway, thereby having overall slower drug absorption than males. Because of the &#8220;flip-flop&#8221; kinetics displayed by long-acting rilpivirine, this slower absorption resulted in lower concentration in females at week 8 (i.e., 4&#160;weeks after the loading dose). Females then exhibited higher concentrations from week 16 and onward. However, as there were no more than a 15% difference in rilpivirine C<sub>trough</sub> levels throughout 48 weeks and the addition of this covariate explained only 11% of the BSV on <inline-formula id="inf79">
<mml:math id="m82" overflow="scroll"><mml:mrow><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>.</mml:mo><mml:mi>m</mml:mi><mml:mo>.</mml:mo><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula>, the effect of sex was not considered clinically relevant and was thus not retained in the final validated model.</p><p>On another note, preliminary model developments showed that the clearance of rilpivirine after i.m. injection was 18% lower than the clearance calculated for oral rilpivirine (with distinct BSV). In addition to being statistically significant, an estimation of the relative bioavailability (<inline-formula id="inf80">
<mml:math id="m83" overflow="scroll"><mml:mrow><mml:msub><mml:mi>F</mml:mi><mml:mtext>oral</mml:mtext></mml:msub></mml:mrow></mml:math>
</inline-formula>) with BSV of oral to i.m. rilpivirine was considered appropriate because it plausibly reflects the biological variability affecting rilpivirine concentrations using the different routes of administration. Indeed, <inline-formula id="inf81">
<mml:math id="m84" overflow="scroll"><mml:mrow><mml:msub><mml:mi>F</mml:mi><mml:mtext>oral</mml:mtext></mml:msub></mml:mrow></mml:math>
</inline-formula> allows correcting for rilpivirine dose, accounts for BSV, and thus also impacts the apparent PK parameters for oral rilpivirine. In particular, it was found that without the introduction of <inline-formula id="inf82">
<mml:math id="m85" overflow="scroll"><mml:mrow><mml:msub><mml:mi>F</mml:mi><mml:mtext>oral</mml:mtext></mml:msub></mml:mrow></mml:math>
</inline-formula> into the model, the central volume of distribution estimate was markedly increased (approximately 3000&#160;L), resulting in biased predictions of rilpivirine concentrations after oral administration. Previously published popPK analyses performed on oral rilpivirine found central volumes of distribution of 321 and 401&#160;L to describe the disposition of rilpivirine (<xref rid="B1" ref-type="bibr">Aouri et al., 2016</xref>; <xref rid="B20" ref-type="bibr">N&#233;ant et al., 2018</xref>), which is consistent with our preliminary development results on oral rilpivirine data showing that a one-compartment model with a central volume of 409&#160;L provided the best model fit. However, because rilpivirine is a highly lipophilic drug (log <italic toggle="yes">p</italic> = 4.86), it is distributed widely into tissue compartments (<xref rid="B11" ref-type="bibr">Eke et al., 2018</xref>). The data collected after i.m. injection probably helped describe the peripheral compartment found in our final model, which included both routes of administration. Lastly, our popPK model shows significant BSV on PK parameters and a modest IOV on <inline-formula id="inf83">
<mml:math id="m86" overflow="scroll"><mml:mrow><mml:mi>C</mml:mi><mml:mi>L</mml:mi></mml:mrow></mml:math>
</inline-formula>, which have not been described before. The inclusion of IOV on the absorption process of long-acting rilpivirine was tested but not retained (i.e., based on statistical significance and model stability). Differences in rilpivirine absorption and/or resorption between occasion within subjects would seem appropriate (e.g., injection-related variability (<xref rid="B16" ref-type="bibr">Jucker et al., 2021</xref>), as well as physiological differences). However, in the absence of more informative data during the absorption phase, an IOV could not be estimated for the i.m. absorption. This probably also explains the modest shrinkage found on <inline-formula id="inf84">
<mml:math id="m87" overflow="scroll"><mml:mrow><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi mathvariant="normal">i</mml:mi><mml:mo>.</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mo>.</mml:mo><mml:mtext>fast</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula> BSV.</p><p>Our popPK model allowed the estimation of t<sub>1/2</sub> for oral rilpivirine of 17&#160;h and 240&#160;h, corresponding to an initial decrease due to diffusion into the peripheral compartment and the onset of elimination and a final decrease due to elimination after equilibrium is reached, respectively. On the other hand, the time to reach a steady state and the t<sub>1/2</sub> of long-acting rilpivirine were estimated using the absorption rate constant of the slowest absorption pathway (<inline-formula id="inf85">
<mml:math id="m88" overflow="scroll"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:msub><mml:mi>a</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>w</mml:mi></mml:mrow></mml:msub></mml:msub></mml:mrow></mml:math>
</inline-formula>). Our model shows that rilpivirine reaches steady-state levels after 1.7 [90% CI: 0.5&#8211;5.7] years and that the t<sub>1/2</sub> is 18.0 [90%CI: 5.5&#8211;59.0] weeks. Although there is a wide range of variability, these values are consistent with those reported in the literature (<xref rid="B12" ref-type="bibr">European Medicines Agency (EMA), 2021a</xref>; <xref rid="B22" ref-type="bibr">Neyens et al., 2021</xref>).</p><p>Our model-based simulations showed that 15% of PWH taking oral rilpivirine would have a C<sub>trough</sub> below the target of 50&#160;ng/mL, which is twice lower than that previously reported by <xref rid="B1" ref-type="bibr">Aouri et al. (2016)</xref>. We hypothesize that, because of the modality of drug administration (i.e., fasting condition because high gastric pH impairs intestinal absorption of rilpivirine (<xref rid="B35" ref-type="bibr">U.S. Food and Drug Administration, 2011</xref>) and the relatively short duration of the oral lead-in period, overall adherence in our study may have been better than in the PWH population of <xref rid="B1" ref-type="bibr">Aouri et al. (2016)</xref>, which received oral rilpivirine in the long term. However, some of the low concentrations observed in PWH on oral rilpivirine might have been caused by impaired adherence. In addition, three PWH enrolled in our study had gastric bypass surgery, and their rilpivirine concentrations were found to be reduced after oral administration, as shown in <xref rid="s12" ref-type="sec">Supplementary Figure S2</xref> (<xref rid="B26" ref-type="bibr">Piso et al., 2023</xref>). This effect was not included in the model because statistical power prevented proper estimation of the PK parameters. Regarding long-acting rilpivirine, our model-based simulations showed that only approximately 50% of rilpivirine C<sub>trough</sub> were above the 50&#160;ng/mL threshold after i.m. injection. This finding is consistent with information from Phase III registrational studies (<xref rid="B9" ref-type="bibr">Cutrell et al., 2021</xref>; <xref rid="B25" ref-type="bibr">Overton et al., 2023</xref>; <xref rid="B23" ref-type="bibr">Orkin et al., 2021</xref>). The results of our analysis indicate that the threshold of 2&#215;PAIC<sub>90</sub> (24&#160;ng/mL) may be a more appropriate target for long-acting rilpivirine C<sub>trough</sub> levels than the 4&#215;PAIC<sub>90</sub> value (50&#160;ng/mL) (<xref rid="B31" ref-type="bibr">Thoueille et al., 2024b</xref>). The latter may be overly alarmist and prompt healthcare providers to discontinue long-acting treatment unnecessarily. Nevertheless, it is important to note that viral failure is still observed in individuals with rilpivirine levels below 50&#160;ng/mL, particularly in PWH who have additional risk factors. Lastly, simulations showed that 5% of PWH would have rilpivirine C<sub>trough</sub> below 2&#215;PAIC<sub>90</sub> (24&#160;ng/mL), which may be of concern.</p><p>Limitations of the present work should be acknowledged. Because the majority of PWH contributed to one sample and no detailed PK sampling was available for oral rilpivirine, the discrimination between BSV and RUV variabilities was limited for oral rilpivirine PK. In addition, because sex was considered clinically irrelevant, the model including this covariate was not validated. Therefore, the results of model-based simulations including sex should be interpreted with caution. Although our study found that no clinical covariate influenced rilpivirine disposition in our real-world cohort from Switzerland, available evidence derived from physiologically-based pharmacokinetic (PBPK) modeling showed that morbidly obese PWH could be at higher risk of presenting suboptimal C<sub>trough</sub> levels (<xref rid="B4" ref-type="bibr">Bettonte et al., 2024a</xref>). Such an effect could not be identified in our study due to the absence of morbidly obese individuals in our population. In addition, another recent PBPK study showed a modest increase in the exposure of long-acting rilpivirine in older compared to younger individuals, which nevertheless does not warrant a dose adjustment (<xref rid="B5" ref-type="bibr">Bettonte et al., 2024b</xref>). Similarly, the small number of older people in our study population may have mitigated the effect of age on rilpivirine PK. Further research is warranted to confirm whether our findings are applicable to populations from other settings. In addition, the design of our study provided limited opportunities to collect early concentrations during the first few days after i.m. injection. The detailed PK investigations revealed variable concentration patterns in some individuals, with some having consistently low plasma concentrations as early as 1&#160;week to 2&#160;weeks after the injection. The underlying cause of these unusual PK profiles remains uncertain within the scope of our analysis. At this time, it remains unclear whether low plasma levels associated with identified or unidentified risk factors could compromise the therapeutic success of long-acting cabotegravir and rilpivirine (<xref rid="B24" ref-type="bibr">Orkin et al., 2023</xref>).</p><p>In conclusion, our study provides the first long-acting rilpivirine concentration-time profiles and their variability in PWH in a routine clinical setting. In accordance with previous results, no covariate was found to clinically influence rilpivirine disposition. A comprehensive discussion of the thresholds to be used in the clinical setting can be found elsewhere (<xref rid="B32" ref-type="bibr">Thoueille et al., 2024a</xref>; <xref rid="B31" ref-type="bibr">Thoueille et al., 2024b</xref>).</p></sec><sec id="s5"><title>5 Group members of the Swiss HIV Cohort Study</title><p>I. Abela, K. Aebi-Popp, A. Anagnostopoulos, M. Battegay, E. Bernasconi, D. L. Braun, H. C. Bucher, A. Calmy, M. Cavassini, A. Ciuffi, G. Dollenmaier, M. Egger, L. Elzi, J. Fehr, J. Fellay, H. Furrer, C. A. Fux, H. F. G&#252;nthard (President of the SHCS), A. Hachfeld, D. Haerry (deputy of &#8220;Positive Council&#8221;), B. Hasse, H. H. Hirsch, M. Hoffmann, I. H&#246;sli, M. Huber, D. Jackson-Perry (patient representatives), C. R. Kahlert (Chairman of the Mother &amp; Child Substudy), L. Kaiser, O. Keiser, T. Klimkait, R. D. Kouyos, H. Kovari, K. Kusejko (Head of Data Centre), N. Labhardt, K. Leuzinger, B. Martinez de Tejada, C. Marzolini, K. J. Metzner, N. M&#252;ller, J. Nemeth, D. Nicca, J. Notter, P. Paioni, G. Pantaleo, M. Perreau, A. Rauch (Chairman of the Scientific Board), L. Salazar-Vizcaya, P. Schmid, R. Speck, M. St&#246;ckle (Chairman of the Clinical and Laboratory Committee), P. Tarr, A. Trkola, G. Wandeler, M. Weisser, and S. Yerly.</p></sec></body><back><ack><p>The authors would like to thank all people with HIV who participated in the study, as well as the physicians, nurses, and data-collecting staff of the SHCS centers in Switzerland and the data- and coordination center of the SHCS for excellent data management and administration.</p></ack><sec sec-type="data-availability" id="s6"><title>Data availability statement</title><p>The datasets presented in this article are not readily available. A request for data sharing can be sent to the Scientific Board of the Swiss HIV Cohort Study. A detailed explanation of the purpose for the request, as well as a study protocol, if applicable, should be presented. The final decision about data release will be taken by the Scientific Board of the SHCS. Requests to access the datasets should be directed to <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.shcs.ch/" ext-link-type="uri">https://www.shcs.ch/</ext-link>.</p></sec><sec sec-type="ethics-statement" id="s7"><title>Ethics statement</title><p>The studies involving humans were approved by the Swiss HIV Cohort Study, Canton&#8217;s Ethics Committee, Lausanne, Switzerland. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p></sec><sec sec-type="author-contributions" id="s8"><title>Author contributions</title><p>PT: Conceptualization, Formal analysis, Methodology, Visualization, writing&#8211;original draft and writing&#8211;review and editing. SS: writing&#8211;review and editing. FS: writing&#8211;review and editing. EC: writing&#8211;review and editing. FV: Data curation, writing&#8211;review and editing. AM: Investigation, writing&#8211;review and editing. MC: Investigation, writing&#8211;review and editing. DB: Investigation, writing&#8211;review and editing. HFG: Investigation, writing&#8211;review and editing. JJDR: Data curation, writing&#8211;review and editing. BS: Investigation, writing&#8211;review and editing. HFG: Investigation, writing&#8211;review and editing. AR: Investigation, writing&#8211;review and editing. PU: Investigation, writing&#8211;review and editing. AC: Investigation, writing&#8211;review and editing. MS: Investigation, writing&#8211;review and editing. CDB: Investigation, writing&#8211;review and editing. EB: Investigation, writing&#8211;review and editing. PS: Investigation, writing&#8211;review and editing. CM: writing&#8211;review and editing. FG: writing&#8211;review and editing. TB: Conceptualization, Formal analysis, Methodology, writing&#8211;review and editing. LAD: Conceptualization, Methodology, Project administration, Funding acquisition, writing&#8211;review and editing. MG: Conceptualization, Formal analysis, Methodology, writing&#8211;review and editing.</p></sec><sec sec-type="COI-statement" id="s10"><title>Conflict of interest</title><p>MC reports grants and payment for expert testimony from Gilead, MSD, and ViiV and support for attending meetings from Gilead, paid to his institution. DB reports honoraria for advisory boards, lectures, and travel grants from the companies Gilead, ViiV, and MSD. HG has received unrestricted research grants from Gilead Sciences and ViiV Healthcare; fees for data and safety monitoring board membership from Merck; consulting/advisory board membership fees from Gilead Sciences, GSK, Johnson and Johnson, Janssen, Novartis, and ViiV Healthcare; and grants from the Yvonne Jacob Foundation, from the National Institutes of Health, and unrestricted research grants from Gilead Sciences. The institution of JD received grants from Gilead Sciences and ViiV. BS reports support for travel grants and advisory boards from Gilead Sciences and ViiV, paid to his institution. The institution of HF received educational grants from ViiV, MSD, AbbVie, Gilead, and Sandoz. MS reports advisory board payments to his institution by Gilead, MSD, ViiV, Moderna, and Pfizer. The institution of AR received grants from Gilead, support for attending meetings from Gilead and Pfizer, and advisory board fees from MSD and Moderna. CM has received speaker honoraria from ViiV, MSD, and Gilead. CD received travel grants for congress participation from Gilead. The institution of EB received grants from the Swiss National Science Foundation; grants from MSD; support for attending meetings from Gilead, MSD, ViiV, and Pfizer; and advisory board fees from Gilead, MSD, ViiV, Pfizer, Moderna, AstraZeneca, Abbvie, and Lilly. The institution of PS received honoraria for advisory board participation and support for attending meetings from ViiV and Gilead. None of those grants and supports was related to the submitted work.</p><p>The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s11"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec id="s12"><title>Supplementary material</title><p>The Supplementary Material for this article can be found online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2024.1437400/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fphar.2024.1437400/full#supplementary-material</ext-link>
</p><supplementary-material id="SM1" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="DataSheet1.pdf" position="float" orientation="portrait"/></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aouri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Barcelo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Guidi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rotger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cavassini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hizrel</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals</article-title>. <source>Antimicrob. agents Chemother.</source><volume>61</volume> (<issue>1</issue>), <fpage>e00899-16</fpage>. <pub-id pub-id-type="doi">10.1128/AAC.00899-16</pub-id><pub-id pub-id-type="pmid">27799217</pub-id><pub-id pub-id-type="pmcid">PMC5192124</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benaboud</surname><given-names>S.</given-names></name><name name-style="western"><surname>Solas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bouchet</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gregoire</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lemaitre</surname><given-names>F.</given-names></name><name name-style="western"><surname>Venisse</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Comment on: population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV</article-title>. <source>J. Antimicrob. Chemother.</source><volume>78</volume>, <fpage>853</fpage>&#8211;<lpage>854</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dkad009</pub-id><pub-id pub-id-type="pmid">36683308</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bergstrand</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hooker</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Wallin</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>M. O.</given-names></name></person-group> (<year>2011</year>). <article-title>Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models</article-title>. <source>AAPS J.</source><volume>13</volume>, <fpage>143</fpage>&#8211;<lpage>151</lpage>. <pub-id pub-id-type="doi">10.1208/s12248-011-9255-z</pub-id><pub-id pub-id-type="pmid">21302010</pub-id><pub-id pub-id-type="pmcid">PMC3085712</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bettonte</surname><given-names>S.</given-names></name><name name-style="western"><surname>Berton</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stader</surname><given-names>F.</given-names></name><name name-style="western"><surname>Battegay</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marzolini</surname><given-names>C.</given-names></name></person-group> (<year>2024a</year>). <article-title>Effect of obesity on the exposure of long-acting cabotegravir and rilpivirine: a modeling study</article-title>. <source>Clin. Infect. Dis.</source><volume>79</volume>, <fpage>477</fpage>&#8211;<lpage>486</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciae060</pub-id><pub-id pub-id-type="pmid">38309958</pub-id><pub-id pub-id-type="pmcid">PMC11327779</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bettonte</surname><given-names>S.</given-names></name><name name-style="western"><surname>Berton</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stader</surname><given-names>F.</given-names></name><name name-style="western"><surname>Battegay</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marzolini</surname><given-names>C.</given-names></name></person-group> (<year>2024b</year>). <article-title>Drug exposure of long-acting cabotegravir and rilpivirine in older people with human immunodeficiency virus: a pharmacokinetic modeling study</article-title>. <source>Open forum Infect. Dis.</source><volume>11</volume>, <fpage>ofae171</fpage>. <pub-id pub-id-type="doi">10.1093/ofid/ofae171</pub-id><pub-id pub-id-type="pmid">38595957</pub-id><pub-id pub-id-type="pmcid">PMC11002946</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bouzom</surname><given-names>F.</given-names></name><name name-style="western"><surname>Laveille</surname><given-names>C.</given-names></name><name name-style="western"><surname>Merdjan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jochemsen</surname><given-names>R.</given-names></name></person-group> (<year>2000</year>). <article-title>Use of nonlinear mixed effect modeling for the meta&#8208;analysis of preclinical pharmacokinetic data: application to S 20342 in the rat</article-title>. <source>J. Pharm. Sci.</source><volume>89</volume>, <fpage>603</fpage>&#8211;<lpage>613</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1520-6017(200005)89:5&amp;#x0003c;603::AID-JPS6&amp;#x0003e;3.0.CO;2-E</pub-id><pub-id pub-id-type="pmid">10756326</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Child</surname><given-names>C. G.</given-names></name><name name-style="western"><surname>Turcotte</surname><given-names>J. G.</given-names></name></person-group> (<year>1964</year>). <article-title>Surgery and portal hypertension</article-title>. <source>Major Probl. Clin. Surg.</source><volume>1</volume>, <fpage>1</fpage>&#8211;<lpage>85</lpage>.<pub-id pub-id-type="pmid">4950264</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Courlet</surname><given-names>P.</given-names></name><name name-style="western"><surname>Alves Saldanha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cavassini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marzolini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Choong</surname><given-names>E.</given-names></name><name name-style="western"><surname>Csajka</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV</article-title>. <source>J. mass Spectrom. JMS</source><volume>55</volume>, <fpage>e4506</fpage>. <pub-id pub-id-type="doi">10.1002/jms.4506</pub-id><pub-id pub-id-type="pmid">32160389</pub-id><pub-id pub-id-type="pmcid">PMC7317362</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cutrell</surname><given-names>A. G.</given-names></name><name name-style="western"><surname>Schapiro</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Perno</surname><given-names>C. F.</given-names></name><name name-style="western"><surname>Kuritzkes</surname><given-names>D. R.</given-names></name><name name-style="western"><surname>Quercia</surname><given-names>R.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis</article-title>. <source>Aids</source><volume>35</volume>, <fpage>1333</fpage>&#8211;<lpage>1342</lpage>. <pub-id pub-id-type="doi">10.1097/qad.0000000000002883</pub-id><pub-id pub-id-type="pmid">33730748</pub-id><pub-id pub-id-type="pmcid">PMC8270504</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dickinson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yapa</surname><given-names>H. M.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moyle</surname><given-names>G.</given-names></name><name name-style="western"><surname>Else</surname><given-names>L.</given-names></name><name name-style="western"><surname>Amara</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Plasma tenofovir, emtricitabine, and rilpivirine and intracellular tenofovir diphosphate and emtricitabine triphosphate pharmacokinetics following drug intake cessation</article-title>. <source>Antimicrob. agents Chemother.</source><volume>59</volume>, <fpage>6080</fpage>&#8211;<lpage>6086</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.01441-15</pub-id><pub-id pub-id-type="pmid">26195515</pub-id><pub-id pub-id-type="pmcid">PMC4576083</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eke</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Chakhtoura</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kashuba</surname><given-names>A.</given-names></name><name name-style="western"><surname>Best</surname><given-names>B. M.</given-names></name><name name-style="western"><surname>Sykes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Rilpivirine plasma and cervicovaginal concentrations in women during pregnancy and postpartum</article-title>. <source>J. Acquir Immune Defic. Syndr.</source><volume>78</volume>, <fpage>308</fpage>&#8211;<lpage>313</lpage>. <pub-id pub-id-type="doi">10.1097/QAI.0000000000001677</pub-id><pub-id pub-id-type="pmid">29528944</pub-id><pub-id pub-id-type="pmcid">PMC6002878</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="webpage"><collab>European Medicines Agency (EMA)</collab> (<year>2021a</year>). <article-title>Rekambys product information</article-title>. <comment>Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ema.europa.eu/en/documents/product-information/rekambys-epar-product-information_en.pdf" ext-link-type="uri">https://www.ema.europa.eu/en/documents/product-information/rekambys-epar-product-information_en.pdf</ext-link> (Accessed February, 2023)</comment>.</mixed-citation></ref><ref id="B13"><mixed-citation publication-type="webpage"><collab>European Medicines Agency (EMA)</collab> (<year>2021b</year>). <article-title>Vocabria product information</article-title>. <comment>Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ema.europa.eu/en/documents/product-information/vocabria-epar-product-information_en.pdf" ext-link-type="uri">https://www.ema.europa.eu/en/documents/product-information/vocabria-epar-product-information_en.pdf</ext-link> (Accessed February, 2023)</comment>.</mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hodge</surname><given-names>D.</given-names></name><name name-style="western"><surname>Back</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Gibbons</surname><given-names>S.</given-names></name><name name-style="western"><surname>Khoo</surname><given-names>S. H.</given-names></name><name name-style="western"><surname>Marzolini</surname><given-names>C.</given-names></name></person-group> (<year>2021</year>). <article-title>Pharmacokinetics and drug&#8211;drug interactions of long-acting intramuscular cabotegravir and rilpivirine</article-title>. <source>Clin. Pharmacokinet.</source><volume>60</volume>, <fpage>835</fpage>&#8211;<lpage>853</lpage>. <pub-id pub-id-type="doi">10.1007/s40262-021-01005-1</pub-id><pub-id pub-id-type="pmid">33830459</pub-id><pub-id pub-id-type="pmcid">PMC8249281</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jonsson</surname><given-names>E. N.</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>M. O.</given-names></name></person-group> (<year>1999</year>). <article-title>Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM</article-title>. <source>Comput. methods programs Biomed.</source><volume>58</volume>, <fpage>51</fpage>&#8211;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1016/s0169-2607(98)00067-4</pub-id><pub-id pub-id-type="pmid">10195646</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jucker</surname><given-names>B. M.</given-names></name><name name-style="western"><surname>Fuchs</surname><given-names>E. J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Damian</surname><given-names>V.</given-names></name><name name-style="western"><surname>Galette</surname><given-names>P.</given-names></name><name name-style="western"><surname>Janiczek</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Multiparametric magnetic resonance imaging to characterize cabotegravir long-acting formulation depot kinetics in healthy adult volunteers</article-title>. <source>Br. J. Clin. Pharmacol.</source><volume>88</volume>, <fpage>1655</fpage>&#8211;<lpage>1666</lpage>. <pub-id pub-id-type="doi">10.1111/bcp.14977</pub-id><pub-id pub-id-type="pmid">34240449</pub-id><pub-id pub-id-type="pmcid">PMC9290983</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levey</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Schmid</surname><given-names>C. H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y. L.</given-names></name><name name-style="western"><surname>Castro</surname><given-names>A. F.</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Feldman</surname><given-names>H. I.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>A new equation to estimate glomerular filtration rate</article-title>. <source>Ann. Intern. Med.</source><volume>150</volume>, <fpage>604</fpage>&#8211;<lpage>612</lpage>. <pub-id pub-id-type="doi">10.7326/0003-4819-150-9-200905050-00006</pub-id><pub-id pub-id-type="pmid">19414839</pub-id><pub-id pub-id-type="pmcid">PMC2763564</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lindbom</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pihlgren</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jonsson</surname><given-names>E. N.</given-names></name></person-group> (<year>2005</year>). <article-title>PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM</article-title>. <source>Comput. methods programs Biomed.</source><volume>79</volume>, <fpage>241</fpage>&#8211;<lpage>257</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmpb.2005.04.005</pub-id><pub-id pub-id-type="pmid">16023764</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Margolis</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Brinson</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>G. H. R.</given-names></name><name name-style="western"><surname>de Vente</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hagins</surname><given-names>D. P.</given-names></name><name name-style="western"><surname>Eron</surname><given-names>J. J.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial</article-title>. <source>Lancet Infect. Dis.</source><volume>15</volume>, <fpage>1145</fpage>&#8211;<lpage>1155</lpage>. <pub-id pub-id-type="doi">10.1016/s1473-3099(15)00152-8</pub-id><pub-id pub-id-type="pmid">26201299</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>N&#233;ant</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gattacceca</surname><given-names>F.</given-names></name><name name-style="western"><surname>L&#234;</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Yazdanpanah</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dhiver</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bregigeon</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine</article-title>. <source>Eur. J. Clin. Pharmacol.</source><volume>74</volume>, <fpage>473</fpage>&#8211;<lpage>481</lpage>. <pub-id pub-id-type="doi">10.1007/s00228-017-2405-1</pub-id><pub-id pub-id-type="pmid">29374296</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>N&#233;ant</surname><given-names>N.</given-names></name><name name-style="western"><surname>Solas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bouazza</surname><given-names>N.</given-names></name><name name-style="western"><surname>L&#234;</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Yazdanpanah</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dhiver</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Concentration&#8211;response model of rilpivirine in a cohort of HIV-1-infected naive and pre-treated patients</article-title>. <source>J. Antimicrob. Chemother.</source><volume>74</volume>, <fpage>1992</fpage>&#8211;<lpage>2002</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dkz141</pub-id><pub-id pub-id-type="pmid">31225609</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neyens</surname><given-names>M.</given-names></name><name name-style="western"><surname>Crauwels</surname><given-names>H. M.</given-names></name><name name-style="western"><surname>Perez-Ruixo</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Rossenu</surname><given-names>S.</given-names></name></person-group> (<year>2021</year>). <article-title>Population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV</article-title>. <source>J. Antimicrob. Chemother.</source><volume>76</volume>, <fpage>3255</fpage>&#8211;<lpage>3262</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dkab338</pub-id><pub-id pub-id-type="pmid">34510179</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orkin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bernal Morell</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>D. H. S.</given-names></name><name name-style="western"><surname>Katner</surname><given-names>H.</given-names></name><name name-style="western"><surname>Stellbrink</surname><given-names>H. J.</given-names></name><name name-style="western"><surname>Belonosova</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study</article-title>. <source>lancet HIV</source><volume>8</volume>, <fpage>e668</fpage>&#8211;<lpage>e678</lpage>. <pub-id pub-id-type="doi">10.1016/S2352-3018(21)00184-3</pub-id><pub-id pub-id-type="pmid">34656207</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orkin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schapiro</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Perno</surname><given-names>C. F.</given-names></name><name name-style="western"><surname>Kuritzkes</surname><given-names>D. R.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>P.</given-names></name><name name-style="western"><surname>DeMoor</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Expanded multivariable models to assist patient selection for long-acting cabotegravir + rilpivirine treatment: clinical utility of a combination of patient, drug concentration, and viral factors associated with virologic failure</article-title>. <source>Clin. Infect. Dis.</source><volume>77</volume>, <fpage>1423</fpage>&#8211;<lpage>1431</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciad370</pub-id><pub-id pub-id-type="pmid">37340869</pub-id><pub-id pub-id-type="pmcid">PMC10654860</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Overton</surname><given-names>E. T.</given-names></name><name name-style="western"><surname>Richmond</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rizzardini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Thalme</surname><given-names>A.</given-names></name><name name-style="western"><surname>Girard</surname><given-names>P. M.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Long-acting cabotegravir and rilpivirine dosed every 2 Months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2M, a randomized, open-label, phase 3b, noninferiority study</article-title>. <source>Clin. Infect. Dis.</source><volume>76</volume>, <fpage>1646</fpage>&#8211;<lpage>1654</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciad020</pub-id><pub-id pub-id-type="pmid">36660819</pub-id><pub-id pub-id-type="pmcid">PMC10156123</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piso</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Thoueille</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Decosterd</surname><given-names>L. A.</given-names></name></person-group> (<year>2023</year>). <article-title>Low Rilpivirine plasma levels in lead-in phase for patients with gastric bypass</article-title>. <source>SSI, SSHH, SSTTM Jt. Annu. Meet.</source></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="book"><article-title>Rilpivirine (oral) PK fact sheet</article-title> (<year>2021</year>). <publisher-name>University of liverpool</publisher-name>. <comment>Revised February 2021</comment>.</mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Savic</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>M. O.</given-names></name></person-group> (<year>2009</year>). <article-title>Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions</article-title>. <source>AAPS J.</source><volume>11</volume>, <fpage>558</fpage>&#8211;<lpage>569</lpage>. <pub-id pub-id-type="doi">10.1208/s12248-009-9133-0</pub-id><pub-id pub-id-type="pmid">19649712</pub-id><pub-id pub-id-type="pmcid">PMC2758126</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scherrer</surname><given-names>A. U.</given-names></name><name name-style="western"><surname>Traytel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Braun</surname><given-names>D. L.</given-names></name><name name-style="western"><surname>Calmy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Battegay</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cavassini</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Cohort profile update: the Swiss HIV cohort study (SHCS)</article-title>. <source>Int. J. Epidemiol.</source><volume>51</volume>, <fpage>33</fpage>&#8211;<lpage>34j</lpage>. <pub-id pub-id-type="doi">10.1093/ije/dyab141</pub-id><pub-id pub-id-type="pmid">34363666</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheiner</surname><given-names>L. B.</given-names></name><name name-style="western"><surname>Beal</surname><given-names>S. L.</given-names></name></person-group> (<year>1981</year>). <article-title>Some suggestions for measuring predictive performance</article-title>. <source>J. Pharmacokinet. Biopharm.</source><volume>9</volume>, <fpage>503</fpage>&#8211;<lpage>512</lpage>. <pub-id pub-id-type="doi">10.1007/BF01060893</pub-id><pub-id pub-id-type="pmid">7310648</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thoueille</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cavassini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guidi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Buclin</surname><given-names>T.</given-names></name><name name-style="western"><surname>Girardin</surname><given-names>F. R.</given-names></name><name name-style="western"><surname>Decosterd</surname><given-names>L. A.</given-names></name><etal/></person-group> (<year>2024b</year>). <article-title>Guidance for the interpretation of long-acting cabotegravir and rilpivirine concentrations based on real-world therapeutic drug monitoring data and documented failures</article-title>. <source>Open forum Infect. Dis.</source><volume>11</volume>. <pub-id pub-id-type="doi">10.1093/ofid/ofae023</pub-id><pub-id pub-id-type="pmcid">PMC10878054</pub-id><pub-id pub-id-type="pmid">38379570</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thoueille</surname><given-names>P.</given-names></name><name name-style="western"><surname>Saldanha</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Schaller</surname><given-names>F.</given-names></name><name name-style="western"><surname>Choong</surname><given-names>E.</given-names></name><name name-style="western"><surname>Munting</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cavassini</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2024a</year>). <article-title>Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland</article-title>. <source>Lancet Regional Health &#8211; Eur.</source><volume>36</volume>, <fpage>100793</fpage>. <pub-id pub-id-type="doi">10.1016/j.lanepe.2023.100793</pub-id><pub-id pub-id-type="pmcid">PMC10757247</pub-id><pub-id pub-id-type="pmid">38162253</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thoueille</surname><given-names>P.</given-names></name><name name-style="western"><surname>Saldanha</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Schaller</surname><given-names>F.</given-names></name><name name-style="western"><surname>Choong</surname><given-names>E.</given-names></name><name name-style="western"><surname>Veuve</surname><given-names>F.</given-names></name><name name-style="western"><surname>Munting</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2024c</year>). <article-title>Population pharmacokinetics of cabotegravir following oral administration and long-acting intramuscular injection in real-world people with HIV</article-title>. <source>Clin. Pharmacol. &amp; Ther.</source><volume>115</volume>, <fpage>1450</fpage>&#8211;<lpage>1459</lpage>. <pub-id pub-id-type="doi">10.1002/cpt.3240</pub-id><pub-id pub-id-type="pmid">38519844</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="webpage"><collab>U.S. Food and Drug Administration</collab> (<year>2022</year>). <article-title>Cabenuva product label</article-title>. <comment>Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212888s005s006lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212888s005s006lbl.pdf</ext-link> (Accessed February, 2023)</comment>.</mixed-citation></ref><ref id="B35"><mixed-citation publication-type="webpage"><collab>U.S. Food and Drug Administration</collab> (<year>2011</year>). <article-title>Edurant product label</article-title>. <comment>Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202022s000lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202022s000lbl.pdf</ext-link> (Accessed August, 2023)</comment>.</mixed-citation></ref><ref id="B36"><mixed-citation publication-type="webpage"><collab>U.S. Food and Drug Administration</collab> (<year>2021</year>). <article-title>Juluca product label</article-title>. <comment>Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210192s011lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210192s011lbl.pdf</ext-link> (Accessed August, 2023)</comment>.</mixed-citation></ref></ref-list></back></article></pmc-articleset>